Paragon 28, Inc. (FNA)
(Real Time Quote from BATS)
$7.58 USD
-0.01 (-0.13%)
Updated Jul 12, 2024 03:55 PM ET
After-Market: $7.57 -0.01 (-0.13%) 4:14 PM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
Paragon 28, Inc. (FNA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$15.50 | $20.00 | $14.00 | 104.22% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Paragon 28, Inc. comes to $15.50. The forecasts range from a low of $14.00 to a high of $20.00. The average price target represents an increase of 104.22% from the last closing price of $7.59.
Analyst Price Targets (6 )
Broker Rating
Paragon 28, Inc. currently has an average brokerage recommendation (ABR) of 1.14 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.14 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, six are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 85.71% and 14.29% of all recommendations. A month ago, Strong Buy made up 85.71%, while Buy represented 14.29%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/FNA.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 6 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.14 | 1.14 | 1.14 | 1.14 | 1.14 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/9/2024 | JMP Securities | David L Turkaly | Strong Buy | Strong Buy |
4/5/2024 | Stephens | George Sellers | Strong Buy | Strong Buy |
3/27/2024 | Piper Sandler | Matthew O'Brien | Strong Buy | Strong Buy |
3/1/2024 | William Blair | Brandon Vazquez | Strong Buy | Strong Buy |
3/1/2024 | Needham & Company | Michael Matson | Moderate Buy | Moderate Buy |
11/8/2023 | Canaccord Genuity | William J Plovanic | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.14 |
ABR (Last week) | 1.14 |
# of Recs in ABR | 7 |
Average Target Price | $15.50 |
LT Growth Rate | 19.60% |
Industry | Medical - Instruments |
Industry Rank by ABR | 103 of 252 |
Current Quarter EPS Est: | -0.15 |